Current status of statin therapy for stroke prevention

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 10, 2011, Pages 1305-1314

  Sett, Aung K ^a   Robinson, Tom G ^a   Mistri, Amit K ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Compliance; Primary prevention; Secondary prevention; Statin; Stroke

Indexed keywords

ATORVASTATIN; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; HUMAN; INTERVENTION STUDY; LIFESTYLE MODIFICATION; LONG TERM CARE; MEDICAL PRACTICE; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCRIPTION; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK; TRIACYLGLYCEROL BLOOD LEVEL;

DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; STROKE;

EID: 80053956173     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.106     Document Type: Review

References (52)

1. Minino AM, Xu J, Kochanek KD. Deaths: preliminary data from 2008. Natl Vital Stat. Rep. 59(2), 1-72 (2010).
2. Carroll K. Stroke incidence and risk factors in a population-based prospective cohort study. Health Stat. Quart. 12, 18-26 (2001).
3. Ramsay SE, Whincup PH, Wannamethee SG et al. Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study. J. Public Health 29(3), 251-257 (2007).
4. Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370(9602), 1829-1839 (2007).
5. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 8(5), 453-463 (2009).
6. No authors listed. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 346(8991-8992), 1647-1653 (1995).
7. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med. 320(14), 904-910 (1989). (Pubitemid 19101595)
8. Imamura T, Doi Y, Arima H et al. LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 40(2), 382-388 (2009).
9. Adams HP Jr, Bendixxen BH, Kappelle LJ et al. Classification of subtype of acute ischaemic stroke. Stroke 24, 35-41 (1993).
10. Heiss G, Sharrett AR, Barnes R, Chambless LE, Szklo M, Alzola C. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am. J. Epidemiol. 134(3), 250-256 (1991).
11. O'Leary DH, Polak JF, Kronmal RA et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 23(12), 1752-1760 (1992).
12. Amarenco P, Benavente O, Goldstein L et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 40, 1405-1409 (2009).
13. Zhang X, Patel A, Horibe H et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int. J. Epidemiol. 32(4), 563-572 (2003). (Pubitemid 37039010)
14. Noda H, Iso H, Irie F et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation 119(16), 2136-2145 (2009).
15. Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? The Kaiser Permanente Medical Care Program. Stroke 27(11), 1993-1998 (1996). (Pubitemid 26372569)
16. Goldstein LB, Amarenco P, Szarek M et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study Neurology 70, 2364-2370 (2008).
17. Labreuche J, Touboul PJ, Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies. Atherosclerosis 203(2), 331-345 (2009).
18. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 300(18), 2142-2152 (2008).
19. Psaty BM, Anderson M, Kronmal RA et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality: the Cardiovascular Health Study. J. Am. Geriatr. Soc. 52(10), 1639-1647 (2004). (Pubitemid 41709916)
20. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 196(2), 489-496 (2008). (Pubitemid 351146660)
21. Chambless LE, Folsom AR, Davis V et al. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. Am. J. Epidemiol. 155(1), 38-47 (2002). (Pubitemid 34042431)
22. Stensland-Bugge E, Bonaa KH, Joakimsen O, Njolstad I. Sex differences in the relationship of risk factors to subclinical carotid atherosclerosis measured 15 years later: the Tromso study. Stroke 31(3), 574-581 (2000). (Pubitemid 30131639)
23. Amarenco P, Goldstein LB, Callahan A III et al. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 204(2), 515-520 (2009).
24. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39-III43 (2004). (Pubitemid 38786442)
25. Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35(12), 2902-2909 (2004). (Pubitemid 39565192)
26. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7-22 (2002).
27. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet 361(9364), 1149-1158 (2003). (Pubitemid 36398384)
28. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435), 685-696 (2004). (Pubitemid 39140624)
29. Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285(13), 1711-1718 (2001). (Pubitemid 32259905)
30. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350(15), 1495-1504 (2004). (Pubitemid 38477774)
31. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360(9346), 1623-1630 (2002). (Pubitemid 35379733)
32. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. Br. Med. J. 328(7440), 634-640 (2004). (Pubitemid 38340037)
33. Goldstein LB, Bushnell CD, Adams RJ et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42(2), 517-584 (2011).
34. Yan B, Parsons M, McKay S et al. When to measure lipid profile after stroke? Cerebrovasc. Dis. 19(4), 234-238 (2005).
35. Marti-Fabregas J, Gomis M, Arboix A et al. Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 35(5), 1117-1121 (2004). (Pubitemid 38543528)
36. Jonsson N, Asplund K. Does pretreatment with statins improve clinical outcome after stroke?: a pilot case-referent study. Stroke 32(5), 1112-1115 (2001). (Pubitemid 32825793)
37. Blanco M, Nombela F, Castellanos M et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 69(9), 904-910 (2007). (Pubitemid 47329591)
38. Amarenco P, Goldstein LB, Szarek M et al. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38(12), 3198-3204 (2007). (Pubitemid 350175737)
39. Paciaroni M, Hennerici M, Agnelli G, Bogousslavsky J. Statins and stroke prevention. Cerebrovasc. Dis. 24(2-3), 170-182 (2007). (Pubitemid 47295581)
40. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM. Fast Assessment of Stroke and Transient Ischaemic Attack to Prevent Early Recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol. 6(11), 961-969 (2007). (Pubitemid 47562312)
41. Chroinin DN, Callaly EL, Duggan J et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke 42, 1021-1029 (2011).
42. Luengo-Fernandez R, Gray AM, Rothwell PM. Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison. Lancet Neurol. 8(3), 235-243 (2009).
43. Adams RJ, Albers G, Alberts MJ et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39(5), 1647-1652 (2008).
44. Ovbiagele B, Hills NK, Saver JL, Johnston SC. Lipid assessment and treatment patterns in hospitalized TIA and ischemic stroke patients. J. Hosp. Med. 1(4), 214-220 (2006).
45. Ovbiagele B, Schwamm LH, Smith EE et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke 41(7), 1508-1513 (2010).
46. Lalouschek W, Lang W, Greisenegger S, Mullner M. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke 34(1), 105-110 (2003). (Pubitemid 36070809)
47. Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 38(10), 2652-2657 (2007). (Pubitemid 47493999)
48. Benner JS, Tierce JC, Ballantyne CM et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics. 22(Suppl. 3), 13-23 (2004). (Pubitemid 39481909)
49. Whitford DL, Hickey A, Horgan F, O'Sullivan B, McGee H, O'Neill D. Is primary care a neglected piece of the jigsaw in ensuring optimal stroke care? Results of a national study. BMC Fam. Pract. 10, 27 (2009).
50. McGinnis B, Olson KL, Magid D et al. Factors related to adherence to statin therapy. Ann. Pharmacother. 41(11), 1805-1811 (2007). (Pubitemid 350044342)
51. Adie K, James MA. Does telephone follow-up improve blood pressure after minor stroke or TIA? Age Ageing 39(5), 598-603 (2010).
52. Joubert J, Reid C, Barton D et al. Integrated care improves risk-factor modification after stroke: initial results of the Integrated Care for the Reduction of Secondary Stroke model. J. Neurol. Neurosurg. Psychiatry 80(3), 279-284 (2009).